Supernus Pharmaceuticals (NASDAQ:SUPN) Given New $63.00 Price Target at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised the price target for Supernus Pharmaceuticals from $46.00 to $63.00, indicating a potential upside of 31.76% from the current stock price.
• The stock currently has an average rating of "Buy" with a consensus price target of $51.50, supported by recent upgrades from multiple analysts.
• Insider trading activity showed CEO Jack A. Khattar sold over 29,000 shares, decreasing his position by 2.52%, while several institutional investors have recently increased their stakes in the company.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) had its price target boosted by equities researchers at Cantor Fitzgerald from $46.00 to $63.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an "overweight" rating on the specialty pharmaceutical company's stock. Cantor Fitzgerald's target price points to a potential upside of 31.76% from the stock's current price.

Several other equities analysts have also commented on SUPN. Piper Sandler upped their price target on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research report on Friday, August 29th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 17th. Finally, Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $51.50.

Supernus Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ:SUPN traded up $0.22 during trading on Tuesday, reaching $47.82. The stock had a trading volume of 79,957 shares, compared to its average volume of 642,551. The business has a fifty day moving average price of $42.32 and a 200-day moving average price of $35.72. The stock has a market cap of $2.68 billion, a P/E ratio of 41.58 and a beta of 0.79. Supernus Pharmaceuticals has a fifty-two week low of $29.16 and a fifty-two week high of $48.44.

Insiders Place Their Bets

In other news, CEO Jack A. Khattar sold 29,513 shares of the business's stock in a transaction on Tuesday, September 23rd. The shares were sold at an average price of $47.23, for a total value of $1,393,898.99. Following the sale, the chief executive officer owned 1,140,883 shares in the company, valued at approximately $53,883,904.09. The trade was a 2.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Frank Mottola sold 5,000 shares of the company's stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $45.87, for a total transaction of $229,350.00. Following the transaction, the senior vice president owned 15,496 shares in the company, valued at approximately $710,801.52. This trade represents a 24.40% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 292,606 shares of company stock worth $12,869,964 in the last 90 days. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Financial Management Professionals Inc. bought a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at about $30,000. Versant Capital Management Inc lifted its holdings in Supernus Pharmaceuticals by 6,931.3% during the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 1,109 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Supernus Pharmaceuticals during the 1st quarter worth $41,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Supernus Pharmaceuticals during the 1st quarter worth $46,000. Finally, EverSource Wealth Advisors LLC bought a new position in shares of Supernus Pharmaceuticals in the second quarter worth $51,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.